By reason of the tumor PD-L1 level is a determinant and a common biomarker for the assessment of the clinical response to anti-PD-L1/PD-1 therapy,7 we screened and found that albendazole (ABZ) could significantly reduce the expression of tumor cell membrane PD-L1 levels. This evidence concerns the gene PDCD1 and neoplasm.